Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Declines By 49.7%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 28,500 shares, a drop of 49.7% from the May 31st total of 56,700 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily volume of 152,500 shares, the days-to-cover ratio is presently 0.2 days.

Virpax Pharmaceuticals Stock Performance

VRPX stock opened at $0.52 on Friday. The firm has a 50 day simple moving average of $1.35 and a 200 day simple moving average of $2.77. Virpax Pharmaceuticals has a 52 week low of $0.46 and a 52 week high of $11.70.

Virpax Pharmaceuticals (NASDAQ:VRPX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($2.75) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, May 22nd.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.